Live market screen
Commercial Space Company Risk / Opportunity Ranking
Opportunity/risk view across launch, satellites, SAR, earth observation, defense demand, financing events, and execution risk.
Updated June 27, 2026
Opportunity view
Showing rows 181-200 of 438; 20 rows per page.
| Rank | Company | Score | Thesis / Evidence |
|---|---|---|---|
| 181 | Earth Eye Co lowweak | Opp 2 Risk 3 | Thesis: The reviewed sources only indicates Earth Eye Co is a Chinese private company associated with the TEE-01B surveillance satellite used for imaging and surveillance. This suggests some asset relevance in Earth observation, but there is no direct business traction or positive catalyst evidence available. Why now: Why now is weak because there are no available post-recent evidence window evidence, no article summaries, and no clear near- or long-horizon catalyst beyond generic association with a surveillance satellite. Caveats: Membership rationale cites article IDs and, but the reviewed sources provide no. Company is private and evidence coverage inside the recent evidence window is empty. |
| 182 | Exquadrum, Inc. lowweak | Opp 2 Risk 2 | Thesis: The reviewed sources rationale describes Exquadrum as a rocket-maker acquired by Mach Industries, which at least indicates strategic relevance to launch/propulsion capabilities if the acquisition meaningfully advances commercialization (: no provided in reviewed sources). Why now: No retained evidence establishes current milestone timing or post-acquisition integration progress, so there is no strong why-now supported in these reviewed sources. Caveats: No current evidence is provided for the cited support article in the reviewed sources. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Acquisition context is weaker than direct operating evidence. |
| 183 | Fergani Space lowweak | Opp 2 Risk 2 | Thesis: Reviewed evidence rationale suggests Fergani Space launched a fifth test satellite into LEO with communications and navigation capabilities, which could indicate technical progress if still current, but no direct post-recent evidence window evidence are available to support a durable 1 year+ opportunity thesis. Why now: There is no credible 'why now' catalyst in the reviewed sources because articles after recent evidence window and evidence after recent evidence window are both zero for this company. The only cited support is older or excluded from the active evidence set: article, referenced in the membership rationale, was outside the kept recent evidence window according to the company coverage report. Caveats: No evidence were available after recent evidence filtering. No representative articles or additional_company_articles were provided. Membership rationale is weaker than direct event/fact evidence. |
| 184 | Filtronic PLC lowweak | Opp 2 Risk 1 | Thesis: Older reviewed sources context says Filtronic is in a space/satellite communications context and has a SpaceX deal via article, which could be positive if current, but there is no retained in-window direct positive evidence with to justify a stronger ranking. Why now: There is no evidenced near-term or durable why-now catalyst inside the retained 90-day evidence window. Caveats: Reviewed evidence references but provides no representative article. Potentially positive older context may be stale or superseded; recency cannot be validated. No retained evidence after recent evidence window. |
| 185 | GalaxEye Space lowweak | Opp 2 Risk 2 | Thesis: The reviewed sources membership rationale describes GalaxEye as launching Mission Drishti, an OptoSAR satellite with defense and disaster-response use cases, which is strategically interesting, but no within the recent evidence window direct evidence is available to support a stronger ranked opportunity. Why now: There is no within the recent evidence window evidence available in these reviewed sources for GalaxEye Space; timing and maturity of current milestones cannot be confirmed from reviewed sources evidence. Caveats: Membership rationale cites article IDs and, but their article content is not provided here for citation. Evidence recent evidence review shows 0 kept rows. This entity may overlap with GalaxEye Space Solutions Private Ltd, but the output contract requires scoring both separately. |
| 186 | GALVANY lowweak | Opp 2 Risk 2 | Thesis: The membership rationale says GALVANY raised a €10M seed in a European tech funding roundup, which is at least a financing signal that could support future execution. However, the reviewed sources explicitly says funding alone is insufficient without a clear space linkage, and there are no available direct evidence after recent evidence window. Why now: The only possible timing angle is the referenced seed raise in the membership rationale, but no -backed available evidence remains after the recent evidence filter, so recency and impact cannot be validated for scoring. Caveats: Membership rationale references article ID: but no is provided in the reviewed sources, so it cannot be cited as factual scoring evidence under the the evidence standard. Funding context does not prove target-cohort fit. |
| 187 | GEOST lowweak | Opp 2 Risk 2 | Thesis: GEOST may retain strategic relevance through its cited prototype development role in space domain awareness and the note that it is now Rocket Lab Optical Systems after acquisition, but the reviewed sources provide no retained recent evidence window-window evidence to support a current standalone upside thesis. Why now: There is no retained within the recent evidence window evidence. Any thesis would rely on older context referenced in the membership rationale, which is insufficient for a stronger rank. Caveats: Reviewed evidence references acquired-business context rather than current standalone operations. No representative articles or retained evidence are included. Low scores reflect missing timely evidence, not a directional call on the business. |
| 188 | GHGSat lowweak | Opp 2 Risk 2 | Thesis: GHGSat likely has strategic relevance as a commercial greenhouse-gas monitoring satellite company, but the reviewed sources includes no available dated evidence to support a stronger opportunity ranking. Why now: The reviewed sources offers no recent evidence window-supported event timing for a why-now view. Caveats: The membership rationale says GHGSat is the world's leading commercial greenhouse gas monitoring satellite company, but the supporting article content is not available here for ranking use. Absence of negative evidence is not positive evidence. |
| 189 | Globalstar lowweak | Opp 2 Risk 2 | Thesis: Globalstar is described in membership rationale as a satellite communications and direct-to-device company, but the reviewed sources includes no available within the recent evidence window positive evidence to support a stronger ranked opportunity view. Why now: No within the recent evidence window evidence were available for Globalstar in these reviewed sources, so there is no current catalyst basis to elevate either opportunity or risk. Caveats: Evidence recent evidence review shows 0 kept rows after the 90-day cutoff. Membership rationale cites article IDs, and: but those article contents are not provided here for direct factual citation. Public company status does not improve ranking without directional evidence. |
| 190 | Guoxing Aerospace Technology lowweak | Opp 2 Risk 2 | Thesis: The reviewed sources rationale says Tencent partners with Guoxing Aerospace for Star Computing AI cloud in an article about space-based AI computing, which could imply exposure to a longer-horizon emerging segment if substantiated by direct evidence (: no provided in reviewed sources). Why now: Space-based AI computing could be strategically relevant over 1 year+, but the reviewed sources provide no retained dated evidence to confirm partnership scope, timing, or commercial milestones. Caveats: No current evidence is provided for the cited support article in the reviewed sources. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Partnership mention alone is insufficient to prove durable company impact. |
| 191 | HawkEye 360, Inc. lowweak | Opp 2 Risk 1 | Thesis: The reviewed sources membership rationale says HawkEye 360 provides RF intelligence/data services and has government-linked business, which could support a durable demand thesis, but no within the recent evidence window evidence or article summaries are available to justify a stronger score. Why now: There is no available post-recent evidence window evidence in the reviewed sources to establish a current catalyst or changed business state. Caveats: No evidence available after recent evidence window. Cannot rely on membership rationale alone for direction. |
| 192 | HawkEye 360, Inc. lowweak | Opp 2 Risk 2 | Thesis: The reviewed sources indicates HawkEye 360 is a space intelligence company with a satellite constellation and government-contract exposure, which could be attractive over a multi-year horizon if contract flow and constellation utilization continue. Why now: The only retained dated item is an April 5, 2026 supporting article context entry stating HawkEye 360 is a data analytics company developing space-based radio frequency mapping and a satellite constellation startup: That is too weak to establish a strong current catalyst. Caveats: Only weak supporting article context is retained after recent evidence window; no direct event/fact evidence is available. Phase2 rationale mentions 30+ satellites and government contracts, but the reviewed sources does not provide those source articles in detail here. |
| 193 | Innoseis lowweak | Opp 2 Risk 1 | Thesis: Innoseis has the strongest limited positive context in this screen because the membership rationale says it raised €6M and has applications in space exploration, with technology selected for future Moon measurements, which could support a long-horizon opportunity if substantiated by direct evidence (: unavailable in reviewed sources). However, the reviewed sources have no direct positive evidence within the recent evidence window, so the thesis remains low confidence. Why now: Potentially relevant because the article context references funding and lunar-measurement selection, but the reviewed sources provide no dated evidence or, so recency and sequence cannot be verified beyond the membership rationale tied to Caveats: No current evidence is provided for cited Zero evidence available after recent evidence window despite the membership rationale. Funding and technology-selection references are article-context level only here. |
| 194 | Intelsat lowweak | Opp 2 Risk 1 | Thesis: The only positive indication in the reviewed sources are membership rationale stating Intelsat participated with Viasat in a Space Force mini-GEO satellite award, which could support a long-horizon government satcom opportunity if current and material, but no direct evidence or article summaries are available after the 90-day recent evidence window. Why now: Why now is weak because coverage data shows 0 article IDs after recent evidence window and 0 evidence available after recent evidence window, so timing and durability cannot be validated from these reviewed sources. Caveats: Membership rationale cites article IDs: and: but the reviewed sources provide no or summaries for them. Evidence recent evidence review shows kept_rows 0 and undated_rows_kept 0, so there is no usable direct evidence inside the ranking window. Cannot treat cohort membership as thesis attractiveness. |
| 195 | Intelsat General lowweak | Opp 2 Risk 2 | Thesis: Reviewed evidence membership rationale says Intelsat General was tied to a Space Force PTS-G satellite contract, which could support long-horizon defense-space opportunity, but no post-recent evidence window evidence or article summaries were available for scoring. Why now: Why-now support is weak because coverage data shows zero article/evidence after the 90-day recent evidence window, so recency for the cited contract context cannot be validated from available evidence. Caveats: Phase2 membership rationale references: but no representative article or evidence row is available after recent evidence window for direct citation. Coverage data reports articles after recent evidence window = 0 and evidence after recent evidence window = 0. Scored low due to evidence absence, not due to negative business evidence. |
| 196 | iQPS lowweak | Opp 2 Risk 1 | Thesis: Membership rationale says Rocket Lab secured a multi-launch agreement with iQPS for SAR satellites, which suggests iQPS may have meaningful constellation deployment activity over a 1 year+ horizon if current. Why now: Why now is limited because the support is only referenced through membership rationale citing articles and, but the reviewed sources provide no or retained evidence after recent evidence window. Caveats: No or article summaries are provided for cited support articles and. Coverage data shows zero retained evidence after recent evidence window. Potentially interesting launch-agreement signal cannot be scored highly without direct reviewed sources evidence. |
| 197 | Jacobs lowweak | Opp 2 Risk 2 | Thesis: Jacobs has evidence of a large Space Force Range Contract award worth up to $4 billion over 10 years, which would ordinarily support a positive thesis, but the relevant articles are dated June 3, 2025 and are outside the reviewed sources' 90-day recent evidence window, so current opportunity support is weak in these reviewed sources. Why now: Why now is weak because the contract evidence is older. The reviewed sources cites Space Force and SpaceNews articles dated June 3, 2025, which are outside the 90-day evidence window Caveats: Contract evidence exists but falls outside the selected 90-day recent evidence window. No direct positive or negative evidence remain after recent evidence filtering. |
| 198 | Jio Platforms lowweak | Opp 2 Risk 2 | Thesis: The reviewed sources rationale says Jio Platforms is the vehicle for Reliance's planned multi-billion-dollar LEO satellite communications entry and planned network to compete with Starlink and Kuiper, which suggests long-horizon optionality if execution proceeds, but no underlying article evidence is provided in these reviewed sources output. Why now: Why now is not well supported in the served evidence because no representative articles or direct evidence are available after recent evidence window despite the membership rationale referencing article IDs, and Caveats: No representative articles or direct evidence are included in the reviewed sources output. Membership rationale is not a substitute for direct thesis evidence. Recency and event sequence cannot be judged from the missing article details. |
| 199 | Karman Holdings Inc. lowweak | Opp 2 Risk 1 | Thesis: Karman Holdings has modest contextual upside because the membership rationale says the reviewed sources placed it in broad space/defense and supply-chain articles and provided revenue facts, which may indicate operating scale or relevance to a durable strategic cycle, unavailable in reviewed sources). But there is no available direct positive evidence after recent evidence window, so this does not support more than a low opportunity score. Why now: Why now is weak because there are no retained evidence after the 90-day cutoff date of March 29, 2026, despite multiple older considered articles. Caveats: No current evidence is provided for and. Revenue facts are referenced only in the membership rationale, not available as direct evidence. Broad supply-chain context is weaker than company-specific contract or product evidence. |
| 200 | Korea Aerospace Industries (KAI) lowweak | Opp 2 Risk 2 | Thesis: Limited opportunity based only on the reviewed sources membership rationale that identifies CAS500-2 as an Earth observation satellite for KAI, indicating confirmed participation in a qualifying satellite activity but not providing a new catalyst, contract, backlog, or financial inflection. Why now: Why now is weak because the reviewed sources say one article supported membership, article ID: but no, timing detail, or direct evidence were available after recent evidence window. Caveats: No direct evidence or article summaries were available after recent evidence window. Membership support references article ID: without a in the reviewed sources. |
Risk view
Showing rows 41-60 of 438; 20 rows per page.
| Rank | Company | Score | Thesis / Evidence |
|---|---|---|---|
| 41 | PLD Space highstrong | Opp 8 Risk 4 | Thesis: Execution risk remains meaningful because the key value inflection still depends on MIURA 5 development and inaugural test-flight timing later in 2026 rather than already-proven orbital commercial cadence. Why now: The reviewed sources show a sequence of material developments: €180 million Series C on March 4, 2026, €30 million EIB venture debt signed April 7, 2026 and reported May 6, 2026/04-07, first commercial contract reported May 21, 2026, and €35 million Kourou launch-complex investment on June 1, 2026 while MIURA 5 remained on track for a late-2026 first test flight. That is strong state-change evidence for a 1 year+ horizon. Evidence
Caveats: Risk evidence is partly inferred from dependency on future launch milestones rather than a disclosed adverse event. Most support is supporting article context, though the chronology is consistent and material. |
| 42 | Rocket Lab USA, Inc. highstrong | Opp 7 Risk 4 | Thesis: Risk is moderate because the reviewed sources' key opportunity is still relatively early in size and scope compared with SpaceX, and execution must extend from launch into GEO satellite production and operation. Why now: The main catalyst is the May 2026 award of Rocket Lab's first GEO satellite production program for the U.S. Space Force, which extends the company into a new orbital regime and broadens its mission model. That is paired with evidence of ongoing launch execution on May 22, 2026 through the ninth dedicated Electron mission for Synspective. Evidence
Caveats: The reviewed sources contain no direct negative events, so risk is mainly execution-based rather than explicitly evidenced adverse news. One representative item references stock performance but is undated and should not be treated as reliable recency proof. |
| 43 | SatSure mediummedium | Opp 7 Risk 4 | Thesis: Risk remains meaningful because the reviewed sources classifies the available evidence mostly as weak supporting article context rather than direct positive events/facts, and there is no available direct evidence for commercial revenue conversion, deployment success, or execution milestones beyond the grant and partnership narratives Why now: Why now is strong because the June 11-22, 2026 evidence sequence shows fresh capital support first, then a later strategic partnership, suggesting opportunity maturation within weeks rather than stale background context Evidence
Caveats: Most evidence is supporting article context or weak context rather than direct positive events. Same-story repetition around the grant should not be treated as independent confirmation. No direct available evidence of revenue, backlog conversion, or deployment milestones. |
| 44 | Scout Space mediummedium | Opp 6 Risk 4 | Thesis: Risk remains meaningful because the reviewed sources' usable support is mostly supporting article context rather than direct positive events, and the financing is growth capital for a private company rather than proof of commercial conversion at scale. Why now: A dated May 6, 2026 article says Scout raised up to $18 million Series A and will use the capital for mission execution and expansion of manufacturing capabilities, creating a current capacity-building milestone for the next year, May 6, 2026). Evidence
Caveats: Most available support is weak context/supporting article context rather than direct positive events. Blue Origin partnership articles are from 2025 and were outside the 90-day recent evidence window, so they should not drive recency-based ranking |
| 45 | Skyroot Aerospace mediummedium | Opp 5 Risk 4 | Thesis: The main risk is launch execution risk because the reviewed sources frames Vikram-1 as a preparation-stage maiden orbital mission rather than an already completed orbital launch, and there is no additional direct evidence in the reviewed sources showing later de-risking. Why now: The relevant dated development is the reported financing on May 7, 2026 alongside the stated approach to the Vikram-1 maiden flight, which fits a 1 year+ thesis if execution progresses. Evidence
Caveats: Support is supporting article context only; the reviewed sources have no direct positive events available for Skyroot. Same-article repeated context rows are not independent confirmation. |
| 46 | SpaceX highstrong | Opp 9 Risk 4 | Thesis: Risk exists from concentration in large government programs and evidence of pricing tension with the Pentagon, but the reviewed sources does not show a material adverse operational or financial event inside the recent evidence window. Why now: The timing is supported by late-May 2026 contract awards: a $2.29 billion Space Force data-network award dated May 26, 2026 and a $4.16 billion Space Force SB-AMTI award dated May 29, 2026/May 30, 2026, plus NASA's plan dated May 24, 2026 to add missions to SpaceX's commercial crew contract, all of which indicate durable backlog expansion and franchise entrenchment over a 1 year+ horizon. Evidence
Caveats: The reviewed sources' available source fields contain no direct positive or negative events for SpaceX; opportunity is inferred from high-materiality neutral facts and article summaries. Ticker mapping is noisy in the reviewed sources: SpaceX is shown with ticker TSLA, which should not be treated as validated public-company identity here. |
| 47 | SpinLaunch lowweak | Opp 4 Risk 4 | Thesis: The same constellation-buildout framing also implies material execution risk because the reviewed sources provide no fresh in-window evidence confirming funding sufficiency, deployment timing, customer demand, or progress beyond the build statement. Why now: There is no direct, dated catalyst in the available evidence. The reviewed sources references article ID: for membership support, but provides no and shows 0 evidence after recent evidence window, so current status cannot be verified. Caveats: No direct evidence available after recent evidence window for this company. Membership rationale references article ID: but the reviewed sources does not include a or summary for citation. |
| 48 | Spire Global, Inc. lowweak | Opp 2 Risk 4 | Thesis: Risk is modestly higher than opportunity because there is effectively no fresh reviewed evidence to validate current traction, contracts, or program wins after the March 29, 2026 cutoff. The issue is not reviewed sources-proven deterioration, but lack of current support. Why now: There is no current catalyst in the kept ranking evidence. The only representative article provided is dated February 7, 2025, outside the recent evidence window, via at Caveats: Zero evidence were kept after the 90-day recent evidence window. The available article context is outside recent evidence window and should not be treated as current catalyst evidence. |
| 49 | Starcloud mediummedium | Opp 6 Risk 4 | Thesis: Starcloud also carries meaningful execution risk because the reviewed sources evidence frames the business around an extremely ambitious proposed constellation scale and supporting article context rather than direct company events. The May 26, 2026 article says the constellation ultimately envisions 88,000 orbital data centers, a very large scope that implies substantial execution and capital intensity risk. Why now: Within the 90-day recent evidence window, Starcloud has the clearest sequence of dated business-state updates: funding on March 30, 2026, network-equipment contract on May 26, 2026, and additional context on capital raised and market positioning on June 10, 2026, For a 1 year+ horizon, that sequence supports an active buildout story even though evidence quality is not fully direct. Evidence
Caveats: All usable evidence is supporting article context; the reviewed sources provide no direct positive or negative dated event/facts. Repeated Starcloud claims across articles are not independent confirmation under the evidence standard. Opportunity and risk both remain dependent on future execution over a long horizon. |
| 50 | Stellar Alpina AG lowweak | Opp 5 Risk 4 | Thesis: The same rationale also implies significant technology and commercialization risk: pre-seed stage, advanced propulsion development, and no available proof of contracts, flight validation, or revenue traction in the reviewed sources. Why now: Why now is relatively better than peers because the rationale includes a recent capital raise and a specific product focus, both of which can influence a 1 year+ strategic trajectory, though no direct dated evidence are available to verify recency sequencing. Caveats: Membership rationale cites article IDs: and: but no are present. The reviewed sources contain no direct positive or negative evidence arrays despite the financing statement in the rationale. Early-stage propulsion development is inherently high-uncertainty, but that is inferred from stage and product type, not from a available adverse article. |
| 51 | TM2SPACE Technologies lowweak | Opp 3 Risk 4 | Thesis: Risk is modest because there is too little available evidence after recent evidence window to support a stronger positive or negative view, making outcome uncertainty high. Why now: The membership rationale references selection for IN-SPACe funding and AI-powered star tracker work using article IDs, and: but no article summaries, or direct evidence are available in these reviewed sources after recent evidence window, so recency and materiality cannot be independently verified from the evidence body. Caveats: No representative articles, or available evidence available to cite directly beyond membership rationale. Coverage debug shows zero article IDs after recent evidence window and zero evidence after recent evidence window. Scoring is conservative because reviewed sources support is incomplete in the visible evidence section. |
| 52 | Tomorrow.io lowweak | Opp 5 Risk 4 | Thesis: Risk remains meaningful because the reviewed sources provide only thin support beyond the financing statement; there is no available kept direct positive event detail, customer traction, deployment milestone, or contract evidence to validate execution progress. Why now: The 'why now' is the capital raise described in the reviewed sources' membership rationale via article: but the ranking payload does not include the article or a richer reviewed evidence row, so recency and detail are only partially grounded. Evidence
Caveats: The reviewed sources does not provide the article for the cited membership-support article. This is mainly a financing-backed opportunity thesis, not a contract- or revenue-backed one in these reviewed sources. |
| 53 | Transcelestial lowweak | Opp 5 Risk 4 | Thesis: Risk is moderately elevated because, despite the promising rationale, the reviewed sources show no representative article details, no direct positive evidence, and zero article IDs after recent evidence window in coverage debug. That creates substantial verification and timing uncertainty. Why now: Why now is only moderate because the membership rationale references support references including, and: but the reviewed sources does not provide or article summaries for them. Without visible dated article detail, the near-current business state cannot be confirmed. Caveats: Important claims appear only in the membership rationale; no -bearing direct evidence is exposed. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. |
| 54 | True Anomaly highstrong | Opp 8 Risk 4 | Thesis: Risk remains meaningful because the company is tied to a demanding defense-space interceptor effort, and one source notes $50 million of the financing was debt, which adds some balance-sheet/obligation risk. In addition, much of the evidence comes from external articles and company-associated announcements rather than a broader set of independently available direct events. Why now: The recent sequence matters: on April 28, 2026, True Anomaly announced a $650 million Series D at a $2.2 billion valuation, also. Then on May 4, 2026, a dated article said the company was selected by the U.S. Space Force Space Systems Command for the Space-Based Interceptor program. That capital-plus-program sequence is directly relevant to a long-horizon growth thesis. Evidence
Caveats: Most evidence is external overlay context/facts rather than primary data source direct events. Several sources repeat the same April 28 financing story and are not independent confirmation of different events. The company-site article is undated, so recency-sensitive claims from it should be treated cautiously. |
| 55 | Unastella lowweak | Opp 5 Risk 4 | Thesis: Even with the stated Series B and launch success, launch-vehicle companies remain execution- and capital-intensive, and the reviewed sources provide no available evidence on follow-on contracts, cadence, or economics. Risk is therefore still elevated. Why now: Why now is relatively stronger because the rationale includes both funding and a technical milestone, which are durable indicators for a 1 year+ horizon, though exact dates and chronology cannot be checked from the reviewed sources' empty post-recent evidence window evidence tables. Caveats: Membership rationale cites article IDs: and: but no are given. No direct events or summaries are available after recent evidence window, so success claims cannot be quoted from the reviewed sources. Opportunity and risk both reflect a capital-intensive launch model with limited reviewed sources verification. |
| 56 | Univity lowweak | Opp 5 Risk 4 | Thesis: The same evidence implies meaningful execution risk: building a satellite network is capital intensive and ambitious, while the reviewed sources offers only one supporting article and no direct follow-on customer, launch, or technical milestone evidence. Why now: Why now is the claimed funding event and network build plan referenced in article ID: but the reviewed sources does not provide the article or detailed timestamp, so recency is only partially grounded. Caveats: The key claim comes from membership rationale rather than available direct evidence. Article ID: is referenced without a. No evidence of downstream execution, contracts, launches, or adoption is present. |
| 57 | Vantor lowweak | Opp 5 Risk 4 | Thesis: Risk is elevated because the reviewed sources does not expose the underlying article summaries or -bearing evidence for those contract claims inside the ranking section, and coverage debug shows zero article IDs after recent evidence window and zero evidence available after recent evidence window. That leaves execution and verification risk high. Why now: Why now is only moderate because the membership rationale references significant contracts via support references including: but the reviewed sources provide no or representative article detail for citation-quality corroboration. The forecast horizon of 1 year+ could fit contract conversion and constellation expansion if current, but recency cannot be validated from visible article rows. Caveats: The contract and expansion claims appear only in membership rationale text; no representative article with is included. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. |
| 58 | Vast Space mediummedium | Opp 6 Risk 4 | Thesis: Risk remains elevated because the same body of context portrays Vast as pursuing multiple capital-intensive initiatives at once—commercial space stations, NASA contract competition, and now satellite manufacturing. Earlier dated March items about a $500 million raise were outside the recent evidence window and therefore cannot be primary support here, so the retained case still relies on supporting article context rather than direct event/facts, leaving execution and commercialization risk significant, May 19, 2026, May 19, 2026). Why now: The timing case is stronger than peers because the product expansion articles are dated May 19, 2026 and May 20, 2026, within the 90-day recent evidence window, and represent a potentially durable strategic change: moving into satellite buses rather than remaining only a station developer, May 19, 2026, May 20, 2026). Evidence
Caveats: Retained evidence is weak context supporting article context; there are no direct positive event/facts available. The March 2026 financing articles are outside the 90-day recent evidence window and cannot be primary support, even though they appear in representative articles. Several retained rows summarize the same basic product announcement and should not be treated as independent confirmation. |
| 59 | WISeKey International Holding AG lowweak | Opp 3 Risk 4 | Thesis: Execution risk appears elevated because the thesis depends on a planned constellation and post-quantum satellite rollout, yet the reviewed sources lack fresh evidence validating current status. With no direct negative event available, the risk score is driven by uncertainty around plan-to-execution conversion rather than confirmed deterioration. Why now: There is no documented near-term catalyst in the available evidence. Membership support cites article IDs and, but the reviewed sources reports 0 article IDs after recent evidence window and 0 evidence after recent evidence window. Caveats: No direct evidence available after recent evidence window for this company. Membership rationale references article IDs and, but the reviewed sources does not include or article summaries for citation. Risk is inferred from lack of current execution proof, not from a confirmed adverse event. |
| 60 | Wyvern lowweak | Opp 4 Risk 4 | Thesis: Risk is moderate because the available evidence is undated supporting article context from the company site. Since the basis is explicitly 'undated,' recency-sensitive claims about current constellation readiness, capacity, and commercial position are uncertain. Why now: Why now is weak because the evidence retained is undated and the reviewed sources explicitly says to treat recency-sensitive claims cautiously when no is available. The underlying strategic area may be attractive, but current business-state confirmation is missing. Evidence
Caveats: Evidence is undated, so current-state claims are less reliable for timing judgments. Only supporting article context is provided, not direct event evidence. No direct customer, contract, financing, or negative-event evidence is shown. |